The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture

References

• Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama. 2001;286:2136–2142. doi: 10.1001/jama.286.17.2136
   PubMed Web of Science ®Google Scholar
• Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62:397–408. doi: 10.1016/j.jacc.2013.05.016
   PubMed Web of Science ®Google Scholar
• Koeth RA, Haselden V, Tang WH. Myeloperoxidase in cardiovascular disease. Adv Clin Chem. 2013;62:1–32. doi: 10.1016/B978-0-12-800096-0.00001-9
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of myeloperoxidase in routine clinical practice. Exp Rev Cardiovascul Ther. 2011;9:223–230. doi: 10.1586/erc.11.2
   PubMedGoogle Scholar
• Narula J, Nakano M, Virmani R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013;61:1041–1051. doi: 10.1016/j.jacc.2012.10.054
   PubMed Web of Science ®Google Scholar
• Silvestre-Roig C, de Winther MP, Weber C, et al. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res. 2014;114:214–226. doi: 10.1161/CIRCRESAHA.114.302355
   PubMed Web of Science ®Google Scholar
• Kolodgie FD, Narula J, Burke AP, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol. 2000;157:1259–1268. doi: 10.1016/S0002-9440(10)64641-X
   PubMed Web of Science ®Google Scholar
• Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016;118:653–667. doi: 10.1161/CIRCRESAHA.115.306256
   PubMed Web of Science ®Google Scholar
• Schrijvers DM, De Meyer GR, Kockx MM, et al. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:1256–1261. doi: 10.1161/01.ATV.0000166517.18801.a7
   PubMed Web of Science ®Google Scholar
• Sluimer JC, Gasc JM, van Wanroij JL, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008;51:1258–1265. doi: 10.1016/j.jacc.2007.12.025
   PubMed Web of Science ®Google Scholar
• Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218:7–29. doi: 10.1002/path.2518
   PubMed Web of Science ®Google Scholar
• Hellings WE, Peeters W, Moll FL, et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation. 2010;121:1941–1950. doi: 10.1161/CIRCULATIONAHA.109.887497
   PubMed Web of Science ®Google Scholar
• Schultz J, Kaminker K. Myeloperoxidase of the leucocyte of normal human blood. I. Content and localization. Arch Biochem Biophys. 1962;96:465–467. doi: 10.1016/0003-9861(62)90321-1
   PubMed Web of Science ®Google Scholar
• Parker H, Albrett AM, Kettle AJ, et al. Myeloperoxidase associated with neutrophil extracellular traps is active and mediates bacterial killing in the presence of hydrogen peroxide. J Leukoc Biol. 2012;91:369–376. doi: 10.1189/jlb.0711387
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Okada Y, Sukhova GK, et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879–891. doi: 10.1016/S0002-9440(10)64036-9
   PubMed Web of Science ®Google Scholar
• Baldus S, Eiserich JP, Mani A, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001;108:1759–1770. doi: 10.1172/JCI200112617
   PubMed Web of Science ®Google Scholar
• Carr AC, Myzak MC, Stocker R, et al. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett. 2000;487:176–180. doi: 10.1016/S0014-5793(00)02227-4
   PubMed Web of Science ®Google Scholar
• Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–541. doi: 10.1172/JCI200421109
   PubMed Web of Science ®Google Scholar
• Chapman AL, Mocatta TJ, Shiva S, et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J Biol Chem. 2013;288:6465–6477. doi: 10.1074/jbc.M112.418970
   PubMed Web of Science ®Google Scholar
• Van AP, Slomianny MC, Boudjeltia KZ, et al. Glycosylation pattern of mature dimeric leukocyte and recombinant monomeric myeloperoxidase: glycosylation is required for optimal enzymatic activity. J Biol Chem. 2010;285:16351–16359. doi: 10.1074/jbc.M109.089748
   PubMed Web of Science ®Google Scholar
• Kooter IM, Koehler BP, Moguilevsky N, et al. The Met243 sulfonium ion linkage is responsible for the anomalous magnetic circular dichroism and optical spectral properties of myeloperoxidase. J Biol Inorg Chem. 1999;4:684–691. doi: 10.1007/s007750050340
   PubMed Web of Science ®Google Scholar
• Kooter IM, Moguilevsky N, Bollen A, et al. Characterization of the Asp94 and Glu242 mutants in myeloperoxidase, the residues linking the heme group via ester bonds. Eur J Biochem. 1999;264:211–217. doi: 10.1046/j.1432-1327.1999.00606.x
   PubMedGoogle Scholar
• Zeng J, Fenna RE. X-ray crystal structure of canine myeloperoxidase at 3 Å resolution. J Mol Biol. 1992;226:185–207. doi: 10.1016/0022-2836(92)90133-5
   PubMed Web of Science ®Google Scholar
• Bolscher BG, Wever R. A kinetic study of the reaction between human myeloperoxidase, hydroperoxides and cyanide. Inhibition by chloride and thiocyanate. Biochim Biophys Acta. 1984;788:1–10. doi: 10.1016/0167-4838(84)90290-5
   PubMed Web of Science ®Google Scholar
• Dunford HB. Heme peroxidases. New York: John Wiley & Sons; 1999.
   Google Scholar
• Fiedler TJ, Davey CA, Fenna RE. X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 A resolution. J Biol Chem. 2000;275:11964–11971. doi: 10.1074/jbc.275.16.11964
   PubMed Web of Science ®Google Scholar
• Furtmüller PG, Zederbauer M, Jantschko W, et al. Active site structure and catalytic mechanisms of human peroxidases. Arch Biochem Biophys. 2006;445:199–213. doi: 10.1016/j.abb.2005.09.017
   PubMed Web of Science ®Google Scholar
• Davies MJ, Hawkins CL, Pattison DI, et al. Mammalian heme peroxidases: from molecular mechanisms to health implications. Antiox Redox Signal. 2008;10:1199–1234. doi: 10.1089/ars.2007.1927
   PubMed Web of Science ®Google Scholar
• Arnhold J, Furtmüller PG, Regelsberger G, et al. Redox properties of the couple compound I/native enzyme of myeloperoxidase and eosinophil peroxidase. Eur J Biochem. 2001;268:5142–5148. doi: 10.1046/j.0014-2956.2001.02449.x
   PubMedGoogle Scholar
• Furtmüller PG, Arnhold J, Jantschko W, et al. Redox properties of the couples compound I/compound II and compound II/native enzyme of human myeloperoxidase. Biochem Biophys Res Commun. 2003;301:551–557. doi: 10.1016/S0006-291X(02)03075-9
   PubMed Web of Science ®Google Scholar
• Segal AW, Geisow M, Garcia R, et al. The respiratory burst of phagocytic cells is associated with a rise in vacuolar pH. Nature. 1981;290:406–409. doi: 10.1038/290406a0
   PubMed Web of Science ®Google Scholar
• Morris JC. The acid ionization constant of HOCl from 5 to 35°. J Phys Chem. 1966;70:3798–3805. doi: 10.1021/j100884a007
   Web of Science ®Google Scholar
• Prütz WA, Kissner R, Koppenol WH, et al. On the irreversible destruction of reduced nicotinamide nucleotides by hypohalous acids. Arch Biochem Biophys. 2000;380:181–191. doi: 10.1006/abbi.2000.1914
   PubMed Web of Science ®Google Scholar
• Nagy P, Jameson GN, Winterbourn CC. Kinetics and mechanisms of the reaction of hypothiocyanous acid with 5-thio-2-nitrobenzoic acid and reduced glutathione. Chem Res Toxicol. 2009;22:1833–1840. doi: 10.1021/tx900249d
   PubMed Web of Science ®Google Scholar
• Morgan PE, Pattison DI, Talib J, et al. High plasma thiocyanate levels in smokers are a key determinant of thiol oxidation induced by myeloperoxidase. Free Radic Biol Med. 2011;51:1815–1822. doi: 10.1016/j.freeradbiomed.2011.08.008
   PubMed Web of Science ®Google Scholar
• van Dalen CJ, Whitehouse MW, Winterbourn CC, et al. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J. 1997;327:487–492. doi: 10.1042/bj3270487
   PubMed Web of Science ®Google Scholar
• Furtmüller PG, Burner U, Obinger C. Reaction of myeloperoxidase compound I with chloride, bromide, iodide, and thiocyanate. Biochemistry. 1998;37:17923–17930. doi: 10.1021/bi9818772
   PubMed Web of Science ®Google Scholar
• Ashby MT, Carlson AC, Scott MJ. Redox buffering of hypochlorous acid by thiocyanate in physiologic fluids. J Am Chem Soc. 2004;126:15976–15977. doi: 10.1021/ja0438361
   PubMed Web of Science ®Google Scholar
• Nagy P, Beal JL, Ashby MT. Thiocyanate is an efficient endogenous scavenger of the phagocytic killing agent hypobromous acid. Chem Res Toxicol. 2006;19:587–593. doi: 10.1021/tx050338c
   PubMed Web of Science ®Google Scholar
• Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol. 2001;31:55–138. doi: 10.1080/20014091111677
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Hampton MB, Livesey JH, et al. Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J Biol Chem. 2006;281:39860–39869. doi: 10.1074/jbc.M605898200
   PubMed Web of Science ®Google Scholar
• Marquez LA, Dunford HB. Reaction of compound III of myeloperoxidase with ascorbic acid. J Biol Chem. 1990;265:6074–6078.
   PubMed Web of Science ®Google Scholar
• Marquez LA, Dunford HB. Interaction of acetaminophen with myeloperoxidase intermediates: optimum stimulation of enzyme activity. Arch Biochem Biophys. 1993;305:414–420. doi: 10.1006/abbi.1993.1440
   PubMed Web of Science ®Google Scholar
• Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol. 2008;4:278–286. doi: 10.1038/nchembio.85
   PubMed Web of Science ®Google Scholar
• Folkes LK, Candeias LP, Wardman P. Kinetics and mechanisms of hypochlorous acid reactions. Arch Biochem Biophys. 1995;323:120–126. doi: 10.1006/abbi.1995.0017
   PubMed Web of Science ®Google Scholar
• Pattison DI, Davies MJ. Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. Chem Res Toxicol. 2001;14:1453–1464. doi: 10.1021/tx0155451
   PubMed Web of Science ®Google Scholar
• Hawkins CL, Pattison DI, Davies MJ. Hypochlorite-induced oxidation of amino acids, peptides and proteins. Amino Acids. 2003;25:259–274. doi: 10.1007/s00726-003-0016-x
   PubMed Web of Science ®Google Scholar
• Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075–2081. doi: 10.1172/JCI119379
   PubMed Web of Science ®Google Scholar
• Thukkani AK, McHowat J, Hsu FF, et al. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation. 2003;108:3128–3133. doi: 10.1161/01.CIR.0000104564.01539.6A
   PubMed Web of Science ®Google Scholar
• Messner MC, Albert CJ, McHowat J, et al. Identification of lysophosphatidylcholine-chlorohydrin in human atherosclerotic lesions. Lipids. 2008;43:243–249. doi: 10.1007/s11745-008-3151-z
   PubMed Web of Science ®Google Scholar
• Winterbourn CC. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of oxidant to hypochlorite. Biochim Biophys Acta. 1985;840:204–210. doi: 10.1016/0304-4165(85)90120-5
   PubMed Web of Science ®Google Scholar
• Peskin AV, Winterbourn CC. Histamine chloramine reactivity with thiol compounds, ascorbate, and methionine and with intracellular glutathione. Free Radic Biol Med. 2003;35:1252–1260. doi: 10.1016/S0891-5849(03)00502-1
   PubMed Web of Science ®Google Scholar
• Peskin AV, Winterbourn CC. Taurine chloramine is more selective than hypochlorous acid at targeting critical cysteines and inactivating creatine kinase and glyceraldehyde-3-phosphate dehydrogenase. Free Radic Biol Med. 2006;40:45–53. doi: 10.1016/j.freeradbiomed.2005.08.019
   PubMed Web of Science ®Google Scholar
• Coker MS, Hu WP, Senthilmohan ST, et al. Pathways for the decay of organic dichloramines and liberation of antimicrobial chloramine gases. Chem Res Toxicol. 2008;21:2334–2343. doi: 10.1021/tx800232v
   PubMed Web of Science ®Google Scholar
• Daugherty A, Dunn JL, Rateri DL, et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437–444. doi: 10.1172/JCI117342
   PubMed Web of Science ®Google Scholar
• Xu J, Xie Z, Reece R, et al. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol. 2006;26:2688–2695. doi: 10.1161/01.ATV.0000249394.94588.82
   PubMed Web of Science ®Google Scholar
• Fu X, Kassim SY, Parks WC, et al. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276:41279–41287. doi: 10.1074/jbc.M106958200
   PubMed Web of Science ®Google Scholar
• Brennan ML, Anderson MM, Shih DM, et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest. 2001;107:419–430. doi: 10.1172/JCI8797
   PubMed Web of Science ®Google Scholar
• Stocker R, Huang A, Jeranian E, et al. Hypochlorous acid impairs endothelium-derived nitric oxide bioactivity through a superoxide-dependent mechanism. Arterioscl Thromb Vasc Biol. 2004;24:2028–2033. doi: 10.1161/01.ATV.0000143388.20994.fa
   PubMed Web of Science ®Google Scholar
• Prasad A, Tsimikas S. Candidate biomarkers for the detection of coronary plaque destabilization and rupture. Curr Atheroscler Rep. 2008;10:309–317. doi: 10.1007/s11883-008-0048-5
   PubMed Web of Science ®Google Scholar
• Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J. 1993;290:165–172. doi: 10.1042/bj2900165
   PubMed Web of Science ®Google Scholar
• Hazell LJ, van den Berg JJM, Stocker R. Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem J. 1994;302:297–304. doi: 10.1042/bj3020297
   PubMed Web of Science ®Google Scholar
• Marsche G, Zimmermann R, Horiuchi S, et al. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem. 2003;278:47562–47570. doi: 10.1074/jbc.M308428200
   PubMed Web of Science ®Google Scholar
• Kawamura M, Heinecke JW, Chait A. Increased uptake of α-hydroxy aldehyde-modified low density lipoprotein by macrophage scavenger receptors. J Lipid Res. 2000;41:1054–1059.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Ho YK, Basu SK, et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76:333–337. doi: 10.1073/pnas.76.1.333
   PubMed Web of Science ®Google Scholar
• Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105:1095–1108. doi: 10.1172/JCI8574
   PubMed Web of Science ®Google Scholar
• Leeuwenburgh C, Hardy MM, Hazen SL, et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem. 1997;272:1433–1436. doi: 10.1074/jbc.272.3.1433
   PubMed Web of Science ®Google Scholar
• Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004;101:13032–13037. doi: 10.1073/pnas.0405292101
   PubMed Web of Science ®Google Scholar
• Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547–1560. doi: 10.1172/JCI5549
   PubMed Web of Science ®Google Scholar
• Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176–1184. doi: 10.1038/nm1637
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. Jama. 2009;302:1993–2000. doi: 10.1001/jama.2009.1619
   PubMed Web of Science ®Google Scholar
• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–135. doi: 10.1056/NEJMoa1001689
   PubMed Web of Science ®Google Scholar
• Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res. 2014;55:168–179. doi: 10.1194/jlr.R039297
   PubMed Web of Science ®Google Scholar
• Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30:151–155. doi: 10.1161/ATVBAHA.108.179226
   PubMed Web of Science ®Google Scholar
• Shao B, Oda MN, Oram JF, et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol. 2010;23:447–454. doi: 10.1021/tx9003775
   PubMed Web of Science ®Google Scholar
• Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813–2820. doi: 10.1161/ATVBAHA.112.300133
   PubMed Web of Science ®Google Scholar
• Malle E, Marsche G, Arnhold J, et al. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta. 2006;1761:392–415. doi: 10.1016/j.bbalip.2006.03.024
   PubMed Web of Science ®Google Scholar
• Pennathur S, Bergt C, Shao B, et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem. 2004;279:42977–42983. doi: 10.1074/jbc.M406762200
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009;50(Suppl):S346-S351.
   PubMed Web of Science ®Google Scholar
• Undurti A, Huang Y, Lupica JA, et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem. 2009;284:30825–30835. doi: 10.1074/jbc.M109.047605
   PubMed Web of Science ®Google Scholar
• Zhang C, Reiter C, Eiserich JP, et al. L-arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem. 2001;276:27159–27165. doi: 10.1074/jbc.M100191200
   PubMed Web of Science ®Google Scholar
• Marsche G, Heller R, Fauler G, et al. 2-Chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol. 2004;24:2302–2306. doi: 10.1161/01.ATV.0000148703.43429.25
   PubMed Web of Science ®Google Scholar
• Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134–1139. doi: 10.1161/01.CIR.0000140262.20831.8F
   PubMed Web of Science ®Google Scholar
• Baldus S, Heitzer T, Eiserich JP, et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med. 2004;37:902–911. doi: 10.1016/j.freeradbiomed.2004.06.003
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Kugiyama K, Aikawa M, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004;24:1309–1314. doi: 10.1161/01.ATV.0000131784.50633.4f
   PubMed Web of Science ®Google Scholar
• Ehrenfeld P, Matus CE, Pavicic F, et al. Kinin B1 receptor activation turns on exocytosis of matrix metalloprotease-9 and myeloperoxidase in human neutrophils: involvement of mitogen-activated protein kinase family. J Leukoc Biol. 2009;86:1179–1189. doi: 10.1189/jlb.0109012
   PubMed Web of Science ®Google Scholar
• Wang Y, Rosen H, Madtes DK, et al. Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J Biol Chem. 2007;282:31826–31834. doi: 10.1074/jbc.M704894200
   PubMed Web of Science ®Google Scholar
• LaFramboise WA, Dhir R, Kelly LA, et al. Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med. 2012;10:157. doi: 10.1186/1741-7015-10-157
   PubMed Web of Science ®Google Scholar
• Kaya MG, Yalcin R, Okyay K, et al. Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J. 2012;39:500–506.
   PubMed Web of Science ®Google Scholar
• Alipour A, Ribalta J, Njo TL, et al. Trans-vessel gradient of myeloperoxidase in coronary artery disease. Eur J ClinInvest. 2013;43:920–925. doi: 10.1111/eci.12121
   PubMed Web of Science ®Google Scholar
• Ruef J, März W, Winkelmann BR. Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study). Scand Cardiovascul J. 2006;40:274–279. doi: 10.1080/14017430600925300
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Mehilli J, et al. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest. 2008;38:90–96. doi: 10.1111/j.1365-2362.2007.01908.x
   PubMed Web of Science ®Google Scholar
• Pawlus J, Holub M, Kozuch M, et al. Serum myeloperoxidase levels and platelet activation parameters as diagnostic and prognostic markers in the course of coronary disease. Int J Lab Hematol. 2010;32:320–328. doi: 10.1111/j.1751-553X.2009.01203.x
   PubMed Web of Science ®Google Scholar
• Samsamshariat SZ, Basati G, Movahedian A, et al. Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease. Biomark Med. 2011;5:377–385. doi: 10.2217/bmm.11.28
   PubMed Web of Science ®Google Scholar
• Tretjakovs P, Jurka A, Bormane I, et al. Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina. Clin Chim Acta. 2012;413:25–29. doi: 10.1016/j.cca.2011.10.009
   PubMed Web of Science ®Google Scholar
• Khan DA, Sharif MS, Khan FA. Diagnostic performance of high-sensitivity troponin T, myeloperoxidase, and pregnancy-associated plasma protein A assays for triage of patients with acute myocardial infarction. Korean J Lab Med. 2011;31:172–178. doi: 10.3343/kjlm.2011.31.3.172
   PubMedGoogle Scholar
• Goldmann BU, Rudolph V, Rudolph TK, et al. Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free Radic Biol Med. 2009;47:79–83. doi: 10.1016/j.freeradbiomed.2009.04.004
   PubMed Web of Science ®Google Scholar
• Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol. 2010;55:1102–1109. doi: 10.1016/j.jacc.2009.11.050
   PubMed Web of Science ®Google Scholar
• Baseri M, Heidari R, Mahaki B, et al. Myeloperoxidase levels predicts angiographic severity of coronary artery disease in patients with chronic stable angina. Adv Biomed Res. 2014;3:137. doi: 10.4103/2277-9175.135155
   PubMedGoogle Scholar
• Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50:159–165. doi: 10.1016/j.jacc.2007.03.033
   PubMed Web of Science ®Google Scholar
• Rebeiz AG, Tamim HM, Sleiman RM, et al. Plasma myeloperoxidase concentration predicts the presence and severity of coronary disease in patients with chest pain and negative troponin-T. Coron Artery Dis. 2011;22:553–558. doi: 10.1097/MCA.0b013e32834c5e98
   PubMed Web of Science ®Google Scholar
• Uydu HA, Bostan M, Yilmaz A, et al. Comparision of inflammatory biomarkers for detection of coronary stenosis in patients with stable coronary artery disease. Eur Rev Med Pharmacol Sci. 2013;17:112–118.
   PubMed Web of Science ®Google Scholar
• Kubala L, Lu G, Baldus S, et al. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta. 2008;394:59–62. doi: 10.1016/j.cca.2008.04.001
   PubMed Web of Science ®Google Scholar
• Wainstein RV, Wainstein MV, Ribeiro JP, et al. Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease. Clin Biochem. 2010;43:57–62. doi: 10.1016/j.clinbiochem.2009.07.022
   PubMed Web of Science ®Google Scholar
• Scharnagl H, Kleber ME, Genser B, et al. Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography—The LURIC study. Int JCardiol. 2014;174:96–105. doi: 10.1016/j.ijcard.2014.03.168
   PubMed Web of Science ®Google Scholar
• Harris PJ, Lee KL, Harrell FE, Jr, et al. Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death. Circulation. 1980;62:718–726. doi: 10.1161/01.CIR.62.4.718
   PubMed Web of Science ®Google Scholar
• Chen LQ, Rohatgi A, Ayers CR, et al. Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study. Atherosclerosis. 2011;219:833–838. doi: 10.1016/j.atherosclerosis.2011.08.029
   PubMed Web of Science ®Google Scholar
• van Velzen JE, de Graaf FR, de Graaf MA, et al. Comprehensive assessment of spotty calcifications on computed tomography angiography: comparison to plaque characteristics on intravascular ultrasound with radiofrequency backscatter analysis. J Nucl Cardiol. 2011;18:893–903. doi: 10.1007/s12350-011-9428-2
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604. doi: 10.1056/NEJMoa035003
   PubMed Web of Science ®Google Scholar
• Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445. doi: 10.1161/01.CIR.0000090690.67322.51
   PubMed Web of Science ®Google Scholar
• Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008;29:1096–1102. doi: 10.1093/eurheartj/ehn071
   PubMed Web of Science ®Google Scholar
• Roman RM, Camargo PV, Borges FK, et al. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis. 2010;21:129–136. doi: 10.1097/MCA.0b013e328333f50d
   PubMed Web of Science ®Google Scholar
• Cavusoglu E, Ruwende C, Eng C, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol. 2007;99:1364–1368. doi: 10.1016/j.amjcard.2006.12.060
   PubMed Web of Science ®Google Scholar
• Liu CN, Chen L, Yang Y, et al. Myeloperoxidase and high-sensitivity C-reactive protein for predicting major adverse cardiovascular events in patients with coronary heart disease. Int J Clin Med. 2015;6:262–270. doi: 10.4236/ijcm.2015.64033
   Google Scholar
• Apple FS, Pearce LA, Chung A, et al. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem. 2007;53:874–881. doi: 10.1373/clinchem.2006.080192
   PubMed Web of Science ®Google Scholar
• Tang WH, Wu Y, Nicholls SJ, et al. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem. 2011;57:33–39. doi: 10.1373/clinchem.2010.152827
   PubMed Web of Science ®Google Scholar
• Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging. 2009;2:1093–1099. doi: 10.1016/j.jcmg.2009.05.012
   PubMed Web of Science ®Google Scholar
• Stefanescu A, Braun S, Ndrepepa G, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J. 2008;155:356–360. doi: 10.1016/j.ahj.2007.10.017
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010;56:946–955. doi: 10.1016/j.jacc.2010.04.048
   PubMed Web of Science ®Google Scholar
• Chang P-Y, Wu T-L, Hung C-C, et al. Development of an ELISA for myeloperoxidase on microplate: normal reference values and effect of temperature on specimen preparation. Clin Chim Acta. 2006;373:158–163. doi: 10.1016/j.cca.2006.05.030
   PubMed Web of Science ®Google Scholar
• Mocatta TJ, Pilbrow AP, Cameron VA, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007;49:1993–2000. doi: 10.1016/j.jacc.2007.02.040
   PubMed Web of Science ®Google Scholar
• Shih J, Datwyler SA, Hsu SC, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem. 2008;54:1076–1079. doi: 10.1373/clinchem.2007.101568
   PubMed Web of Science ®Google Scholar
• Scheffer PG, van der Zwan LP, Schindhelm RK, et al. Myeloperoxidase concentrations in EDTA-plasma of healthy subjects are discordant with concentrations in heparin-plasma and serum. Clin Biochem. 2009;42:1490–1492. doi: 10.1016/j.clinbiochem.2009.06.004
   PubMed Web of Science ®Google Scholar
• Léculier C, Couprie N, Adeleine P, et al. The effects of high molecular weight- and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes. Thromb Res. 1993;69:519–531. doi: 10.1016/0049-3848(93)90056-T
   PubMed Web of Science ®Google Scholar
• Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871–1878. doi: 10.1161/CIRCULATIONAHA.105.590083
   PubMed Web of Science ®Google Scholar
• Goiffon RJ, Martinez SC, Piwnica-Worms D. A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma. Nat Commun. 2015;6:6271. doi: 10.1038/ncomms7271
   PubMed Web of Science ®Google Scholar
• Chevrier I, Tregouet DA, Massonnet-Castel S, et al. Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for atherosclerosis? Atherosclerosis. 2006;188:150–154. doi: 10.1016/j.atherosclerosis.2005.10.012
   PubMed Web of Science ®Google Scholar
• Piedrafita FJ, Molander RB, Vansant G, et al. An alu element in the myeloperoxidase promoter contains a vcmposite SP1-thyroid hormone-retinoic acid response element. J Biol Chem. 1996;271:14412–14420. doi: 10.1074/jbc.271.24.14412
   PubMed Web of Science ®Google Scholar
• Kettle AJ, Albrett AM, Chapman AL, et al. Measuring chlorine bleach in biology and medicine. Biochim Biophys Acta. 2014;1840:781–793. doi: 10.1016/j.bbagen.2013.07.004
   PubMed Web of Science ®Google Scholar
• Kettle AJ. Neutrophils convert tyrosyl residues in albumin to chlorotyrosine. FEBS Lett. 1996;379:103–106. doi: 10.1016/0014-5793(95)01494-2
   PubMed Web of Science ®Google Scholar
• Fu S, Wang H, Davies M, et al. Reactions of hypochlorous acid with tyrosine and peptidyl-tyrosyl residues give dichlorinated and aldehydic products in addition to 3- chlorotyrosine. J Biol Chem. 2000;275:10851–10858. doi: 10.1074/jbc.275.15.10851
   PubMed Web of Science ®Google Scholar
• Mani AR, Ippolito S, Moreno JC, et al. The metabolism and dechlorination of chlorotyrosine in vivo. J Biol Chem. 2007;282:29114–29121. doi: 10.1074/jbc.M704270200
   PubMed Web of Science ®Google Scholar
• Nickelsen MG, Nweke A, Scully FE, Jr, et al. Reactions of aqueous chlorine in vitro in stomach fluid from the rat: chlorination of tyrosine. Chem Res Toxicol. 1991;4:94–101. doi: 10.1021/tx00019a013
   PubMed Web of Science ®Google Scholar
• Shao B, Fu X, McDonald TO, et al. Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I. J Biol Chem. 2005;280:36386–36396. doi: 10.1074/jbc.M508169200
   PubMed Web of Science ®Google Scholar
• Shao B, Pennathur S, Heinecke JW. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for dite-dpecific oxidation in human atherosclerotic lesions. J Biol Chem. 2012;287:6375–6386. doi: 10.1074/jbc.M111.337345
   PubMed Web of Science ®Google Scholar
• Shao B, Tang C, Sinha A, et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res. 2014;114:1733–1742. doi: 10.1161/CIRCRESAHA.114.303454
   PubMed Web of Science ®Google Scholar
• Nagan N, Zoeller RA. Plasmalogens: biosynthesis and functions. Prog Lipid Res. 2001;40:199–229. doi: 10.1016/S0163-7827(01)00003-0
   PubMed Web of Science ®Google Scholar
• Albert CJ, Crowley JR, Hsu F-F, et al. Reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: identification of 2-chlorohexadecanal. J Biol Chem. 2001;276:23733–23741. doi: 10.1074/jbc.M101447200
   PubMed Web of Science ®Google Scholar
• Wildsmith KR, Albert CJ, Anbukumar DS, et al. Metabolism of myeloperoxidase-derived 2-chlorohexadecanal. J Biol Chem. 2006;281:16849–16860. doi: 10.1074/jbc.M602505200
   PubMed Web of Science ®Google Scholar
• Thukkani AK, Albert CJ, Wildsmith KR, et al. Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein. J Biol Chem. 2003;278:36365–36372. doi: 10.1074/jbc.M305449200
   PubMed Web of Science ®Google Scholar
• Brahmbhatt VV, Albert CJ, Anbukumar DS, et al. ω-Oxidation of α-chlorinated fatty acids: identifiction of α-chlorinated dicarboxylic acids. J Biol Chem. 2010;285:41255–41269. doi: 10.1074/jbc.M110.147157
   PubMed Web of Science ®Google Scholar
• Harwood DT, Kettle AJ, Winterbourn CC. Production of glutathione sulfonamide and dehydroglutathione from GSH by myeloperoxidase-derived oxidants and detection using a novel LC-MS/MS method. Biochem J. 2006;399:161–168. doi: 10.1042/BJ20060978
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Brennan SO. Characterization of the oxidation products of the reaction between reduced glutathione and hypochlorous acid. Biochem J. 1997;326:87–92. doi: 10.1042/bj3260087
   PubMed Web of Science ®Google Scholar
• Harwood DT, Darlow BA, Cheah F-C, et al. Biomarkers of neutrophil-mediated glutathione and protein oxidation in tracheal aspirates from preterm infants: association with bacterial infection. Pediatr Res. 2011;69:28–33. doi: 10.1203/PDR.0b013e3181ff2378
   PubMed Web of Science ®Google Scholar
• Kettle AJ, Turner R, Gangell CL, et al. Oxidation contributes to low glutathione in the airways of children with cystic fibrosis. Eur Respir J. 2014;44:122–129. doi: 10.1183/09031936.00170213
   PubMed Web of Science ®Google Scholar
• Pulli B, Ali M, Forghani R, et al. Measuring myeloperoxidase activity in biological samples. PLoS ONE. 2013;8:e67976. doi: 10.1371/journal.pone.0067976
   PubMed Web of Science ®Google Scholar
• Franck T, Kohnen S, Boudjeltia KZ, et al. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Talanta. 2009;80:723–729. doi: 10.1016/j.talanta.2009.07.052
   PubMed Web of Science ®Google Scholar
• Franck T, Minguet G, Delporte C, et al. An immunological method to combine the measurement of active and total myeloperoxidase on the same biological fluid, and its application in finding inhibitors which interact directly with the enzyme. Free Radic Res. 2015;49:790–799. doi: 10.3109/10715762.2015.1027197
   PubMed Web of Science ®Google Scholar
• Flemmig J, Remmler J, Zschaler J, et al. Detection of the halogenating activity of heme peroxidases in leukocytes by aminophenyl fluorescein. Free Radic Res. 2015;49:768–776. doi: 10.3109/10715762.2014.999676
   PubMed Web of Science ®Google Scholar
• Maghzal GJ, Cergol KM, Shengule SR, et al. Assessment of myeloperoxidase activity by the conversion of hydroethidine to 2-chloroethidium. J Biol Chem. 2014;289:5580–5595. doi: 10.1074/jbc.M113.539486
   PubMed Web of Science ®Google Scholar
• Talib J, Maghzal GJ, Cheng D, et al. Detailed protocol to assess in vivo and ex vivo myeloperoxidase activity in mouse models of vascular inflammation and disease using hydroethidine. Free Radic Biol Med. 2016;97:124–135. doi: 10.1016/j.freeradbiomed.2016.05.004
   PubMed Web of Science ®Google Scholar
• Shepherd J, Hilderbrand SA, Waterman P, et al. A fluorescent probe for the detection of myeloperoxidase activity in atherosclerosis-associated macrophages. Chem Biol. 2007;14:1221–1231. doi: 10.1016/j.chembiol.2007.10.005
   PubMedGoogle Scholar
• Hu JJ, Wong N-K, Gu Q, et al. HKOCl-2 series of green BODIPY-based fluorescent probes for hypochlorous acid detection and imaging in live cells. Org Lett. 2014;16:3544–3547. doi: 10.1021/ol501496n
   PubMed Web of Science ®Google Scholar
• Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–235. doi: 10.1056/NEJMoa1002358
   PubMed Web of Science ®Google Scholar
• Otsuka F, Joner M, Prati F, et al. Clinical classification of plaque morphology in coronary disease. Nat Rev Cardiol. 2014;11:379–389. doi: 10.1038/nrcardio.2014.62
   PubMed Web of Science ®Google Scholar
• Cameron A, Davis KB, Green G, et al. Coronary bypass surgery with internal-thoracic-artery grafts-effects on survival over a 15-year period. N Engl J Med. 1996;334:216–220. doi: 10.1056/NEJM199601253340402
   PubMed Web of Science ®Google Scholar
• Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516. doi: 10.1056/NEJMoa070829
   PubMed Web of Science ®Google Scholar
• De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001. doi: 10.1056/NEJMoa1205361
   PubMed Web of Science ®Google Scholar
• Querol M, Chen JW, Bogdanov AA, Jr. A paramagnetic contrast agent with myeloperoxidase-sensing properties. Org Biomol Chem. 2006;4:1887–1895. doi: 10.1039/b601540a
   PubMed Web of Science ®Google Scholar
• Nahrendorf M, Sosnovik D, Chen JW, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation. 2008;117:1153–1160. doi: 10.1161/CIRCULATIONAHA.107.756510
   PubMed Web of Science ®Google Scholar
• Ronald JA, Chen JW, Chen Y, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation. 2009;120:592–599. doi: 10.1161/CIRCULATIONAHA.108.813998
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Nilges M, Weissleder R, et al. Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity. J Am Chem Soc. 2010;132:168–177. doi: 10.1021/ja905274f
   PubMed Web of Science ®Google Scholar
• Breckwoldt MO, Chen JW, Stangenberg L, et al. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci U S A. 2008;105:18584–18589. doi: 10.1073/pnas.0803945105
   PubMed Web of Science ®Google Scholar
• Su HS, Nahrendorf M, Panizzi P, et al. Vasculitis: molecular imaging by targeting the inflammatory enzyme myeloperoxidase. Radiology. 2012;262:181–190. doi: 10.1148/radiol.11110040
   PubMed Web of Science ®Google Scholar
• Chen YC, Bui AV, Diesch J, et al. A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling. Circ Res. 2013;113:252–265. doi: 10.1161/CIRCRESAHA.113.301562
   PubMed Web of Science ®Google Scholar
• Yildiz G, Demiryurek AT. Ferrous iron-induced luminol chemiluminescence: a method for hydroxyl radical study. J Pharmacol Toxicol Methods. 1998;39:179–184. doi: 10.1016/S1056-8719(98)00025-2
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Ames BN. Detection of lipid hydroperoxides and hydrogen peroxide at picamole levels by an HPLC and isoluminol chemiluminescence assay. Free Radic Biol Med. 1987;3:359–361. doi: 10.1016/S0891-5849(87)80048-5
   PubMed Web of Science ®Google Scholar
• Wardman P. Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: progress, pitfalls, and prospects. Free Radic Biol Med. 2007;43:995–1022. doi: 10.1016/j.freeradbiomed.2007.06.026
   PubMed Web of Science ®Google Scholar
• Gerber CE, Kuci S, Zipfel M, et al. Phagocytic activity and oxidative burst of granulocytes in persons with myeloperoxidase deficiency. Eur J Clin Chem Clin Biochem. 1996;34:901–908.
   PubMedGoogle Scholar
• Gross S, Gammon ST, Moss BL, et al. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat Med. 2009;15:455–461. doi: 10.1038/nm.1886
   PubMed Web of Science ®Google Scholar
• Zhang N, Francis KP, Prakash A, et al. Enhanced detection of myeloperoxidase activity in deep tissues through luminescent excitation of near-infrared nanoparticles. Nat Med. 2013;19:500–505. doi: 10.1038/nm.3110
   PubMed Web of Science ®Google Scholar
• Koide Y, Urano Y, Hanaoka K, et al. Development of an Si-rhodamine-based far-red to near-infrared fluorescence probe selective for hypochlorous acid and its applications for biological imaging. J Am Chem Soc. 2011;133:5680–5682. doi: 10.1021/ja111470n
   PubMed Web of Science ®Google Scholar
• Stocker R, Keaney JF, Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381–1478. doi: 10.1152/physrev.00047.2003
   PubMed Web of Science ®Google Scholar
• Tang WHW, Iqbal N, Wu Y, et al. Usefulness of cardiac biomarker score for risk stratification in stable patients undergoing elective cardiac evaluation across glycemic status. Am J Cardiol. 2013;111:465–470. doi: 10.1016/j.amjcard.2012.10.027
   PubMed Web of Science ®Google Scholar
• Düzgünçinar O, Yavuz B, Hazirolan T, et al. Plasma myeloperoxidase is related to the severity of coronary artery disease. Acta Cardiol. 2008;63:147–152. doi: 10.2143/AC.63.2.2029520
   PubMed Web of Science ®Google Scholar